Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

MGF vs PEG-MGF

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

This combination is flagged

Two IGF-1 analogs in the same regimen: Moderate-High risk per peptide research literature. Multiple IGF-1 analogs compete for the same IGF-1R pool; the second analog does not raise peak receptor activation but stacks hypoglycemia exposure, cardiac/renal/hepatic hypertrophy signal, and peripheral neuropathy risk in heavy stacks.

Data-derived verdict

MGF and PEG-MGF share the igf-1 class and carry roughly equivalent evidence (Preclinical + Anecdotal / Anecdotal). On the catalogued data layer MGF has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; MGF's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

MGF

Preclinical + Anecdotal

PEG-MGF

Anecdotal

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

MGF PEG-MGF
Class IGF-1 splice variant peptide; anabolic Pegylated IGF-1 splice variant; anabolic
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism Local muscle IGF-1 splice variant; activates satellite cells after mechanical damage PEG conjugation extends half-life of MGF for systemic action
Route IM (localized) SC / IM
Half-life ~5-7 min ~2-3 days
Dosage (research) 100-400 mcg post-workout IM into target muscle 200-400 mcg SC 1-2x weekly
Evidence tier Preclinical + Anecdotal Anecdotal
Research depth 68 indexed (PubMed 60 · CT 0 · EPMC 8) 1 indexed (PubMed 0 · CT 0 · EPMC 1)
Availability Research Chemical Research Chemical
Reported risks Very short half-life; injection site only; limited human data Immunogenicity concerns with PEG; limited safety data

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick MGF or PEG-MGF?

MGF and PEG-MGF share the igf-1 class and carry roughly equivalent evidence (Preclinical + Anecdotal / Anecdotal). On the catalogued data layer MGF has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; MGF's evidence base is currently denser.

What is the difference between MGF and PEG-MGF?

MGF is classed as IGF-1 splice variant peptide; anabolic; PEG-MGF is classed as Pegylated IGF-1 splice variant; anabolic. Reported mechanism: MGF, Local muscle IGF-1 splice variant; activates satellite cells after mechanical damage; PEG-MGF, PEG conjugation extends half-life of MGF for systemic action. Reported half-life: MGF, ~5-7 min; PEG-MGF, ~2-3 days. Routes in published studies: MGF, IM (localized); PEG-MGF, SC / IM.

Which has stronger evidence, MGF or PEG-MGF?

PEG-MGF has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. MGF is graded Preclinical + Anecdotal, with 2 cited sources on its reference page and 68 indexed studies. PEG-MGF is graded Anecdotal, with 1 cited source on its reference page and 1 indexed studies.

Which is more accessible, MGF or PEG-MGF?

Neither MGF nor PEG-MGF is an FDA-approved drug. Catalog status: MGF, Research Chemical; PEG-MGF, Research Chemical. PEG-MGF's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.

Are MGF and PEG-MGF ever combined?

MGF and PEG-MGF appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two IGF-1 analogs in the same regimen, moderate-high risk.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…